tage
implementation
taken
london
fluoroimmunometric
medicine
conclusions
shown
threshold
mi
exercise
dormandy
311
fibrinogen
befroy
sided
2002
denmark
mayerson
ratner
rate
steering
density
sensitivity
people
treated
bmi
local
essex
outcome
education
ldl
allowing
whom
gomis
show
even
eligible
rosiglitazone
rose
better
272
curtis
already
turner
exploitation
diagnosed
drugs
arms
discontinuation
sd
comparator
dade
table
physicians
substantial
cusi
references
country
explains
089
dme
agent
met
or
could
128
rates
studien
cv
research
ja
hopital
1557
laws
procedures
both
ments
heston
male
prior
stimulated
assays
sipila
esterified
would
rb
significantly
concentra
412
global
stimulating
pancreatic
2791
kinetics
third
dense
1289
disease
dr
jones
approach
efficacy
elsewhere
predefined
prevention
ceasing
rosiglita
age
281
difficulties
higher
sm
adding
tests
results
cholesterol
appear
equation
cook
modelling
transformed
right
haffner
extent
measures
thursday
detectable
recommendations
affected
who
previously
plasma
419
837
149
increases
routine
laboratories
database
failure
factors
institutions
1998
pre
studies
expenses
action
brunetti
fat
intensive
br
inconsistency
activities
hpi
initiated
college
freed
idf
appreciated
36s
139
926
178
san
mellitus
patient
2500
possibility
presented
stampfer
populations
113
surrogate
committees
noticeable
conservative
composition
ncd
alone
combination
lipolysis
1258
frighi
md
lifestyle
beyond
endocrinology
original
increase
phenotype
hbn
wise
doi
2001
published
cary
hdl
months
later
asymmetric
dcct
hp
members
containing
split
aes
anxiety
fb
proportions
excluding
contrast
hygiene
pdh
withdrawn
move
facto
its
obes
determined
observations
1122
typically
zone
263
group
trajectory
remunerated
toxicity
accepted
medical
permit
end
respective
reach
than
6s52
effective
hepatic
department
guiding
matsuda
reduction
follow
continued
strength
062
rapid
2000
concentration
hplc
resistance
methodology
consent
strata
underlying
practice
order
following
bio
restrictions
data
preferential
glycaemic
concealed
basal
1565
after
4hh
benedetti
as
ae
respond
permitted
atorvastatin
opportunity
difference
initiatives
1997
allocated
endocrine
takes
assessment
immunoassay
skeletal
document
new
centre
respectively
needed
acids
prospective
conclusion
wide
responders
homeostasis
actual
rc
framlington
1093
accordingly
differ
haemoglobin
resulted
criteria
triglyceride
generally
changed
952
consistent
253
eight
2427
assay
interpret
compared
combinations
did
marcovina
cull
method
neuss
blinded
more
subjects
cross
groups
141
regarding
september
most
demonstrate
had
802
biopool
measurement
again
employees
phase
much
explained
part
left
drug
upon
untypical
236
resumed
lebon
enzyme
means
sometimes
analyses
reasonable
sustained
003
good
overlap
intention
dependent
260
qzentrum
associated
deposition
increasing
esterase
preparation
degrees
least
less
helsinki
400
analysis
633
introduction
fixed
declaration
paper
value
oral
antonio
overview
2210
customs
company
progressive
quantified
maintaining
cohen
termed
individuals
secondary
some
zambanini
hazuda
committee
function
instantaneous
homa
improvement
non
glass
against
maisey
failing
label
friedewald
missing
tolerability
rg
ridker
adherence
censored
likely
shorter
responded
037
259
levels
und
rapidly
philip
strengths
se
multicentre
france
des
creative
randomization
product
mahankali
course
lowering
titrated
lower
herman
specific
pc
thiazolidinediones
design
interests
hardies
american
withdrew
schernthaner
colorimetric
pj
other
significance
term
628
oxford
chemicals
allocation
university
630
another
rr
target
cardiovascular
entered
raji
clinically
behring
vascu
sulfonylurea
commercial
stratified
finland
hypertensive
1456
favour
titration
well
zealand
beck
progressed
potential
australia
297
5491
none
followed
dme_2160
towards
optical
ncs
completer
world
greatest
marker
early
fig
additionally
form
confirmation
figure
annual
being
constructed
europid
preset
ongoing
dufour
226
cant
cardiac
man
ba
windows
possibly
itt
1999
may
different
worsened
terms
miscellaneous
ace
reinforcement
glibenclamide
haemostasis
glimepiride
int
number
579
error
organization
comparative
managed
population
test
event
stern
their
relating
excludes
included
richards
265
pressure
2012
also
sensitizer
distribution
related
but
too
advocated
over
reaching
quest
criterion
prevent
albeit
improving
accordance
statistical
matrix
ltdstudy
parameters
burke
include
352
evidence
jc
947
europe
rise
fpg
galloway
based
comparisons
assigned
632
complications
unit
797
made
page
diabet
logistic
urquhart
turku
such
greater
degree
lowers
equivalent
current
sponsor
assessed
rad
time
maintain
sulphonylurea
aace
human
twice
diagram
tan
cell
apparent
perkin
showed
international
rs
has
reaction
visceral
2007
assessments
macro
achieve
gc
tablets
declining
im
medication
grant
ne2
emphasizes
use
pitie
markedly
harlow
publishing
week
despite
assoc
until
covariance
goals
confounded
1735
paradox
massi
hallmark
steadying
panels
confidence
therapy
diabetologia
glycaemia
events
rare
inferior
whilst
antigen
bekins
subsequently
randomized
observed
clot
40s
established
mean
began
kit
involves
onset
np
range
micronized
macrovascular
particularly
moved
effect
tolerated
gw
134
gain
kahn
abstract
major
place
primary
above
particles
greenford
proinsulin
sp
monotherapy
participant
previous
reduce
studied
board
res
setting
preparations
type
reactive
supported
nature
there
advan
246
vascular
meeting
triglycerides
confirmed
moules
authors
3485
diagnostics
001
301
calculated
intervals
biorad
366
interest
barcelona
poor
pharmaceuticals
therapies
men
newcastle
clinical
index
off
known
greece
lipids
differences
additional
pm
signifi
visits
correspondence
mmol
biomedical
reporting
lipid
improves
inferiority
line
result
330
prothrombotic
reflecting
text
findings
detail
ceased
need
centres
fatty
does
dc
per
performed
ukpds
fewer
whereas
interaction
plasminogen
626
principally
trials
257
arisen
klinische
activator
metabolism
sensitive
margin
difficult
deviations
eb
mm
statistics
power
arranging
telephone
although
period
3479
presents
owing
comparison
all
ka
2006
units
2550
202
total
add
including
control
nefa
endpoints
restoration
content
supportive
df
integrity
tyne
institutional
metabolic
during
multiple
miyazaki
chosen
methods
recently
duration
rising
durability
attribution
open
significant
importantly
magnitude
participating
hercules
pai
284
impaired
post
1249
kreider
secretion
connection
they
adopt
definition
inhibitor
adverse
1104
diagnosis
fuer
clinic
according
predicted
pract
showing
suggest
patwardhan
manufacturer
je
matched
withdrawals
main
classification
rudenski
odense
charbonnel
mail
substantially
effects
receiving
ns
protein
newly
schulze
arch
median
conventional
normality
tested
system
month
enrolled
model
appears
ma
pmol
addition
risk
algorithms
care
beginning
1015
024
inhibited
highly
measured
study
arm
affect
outcomes
152
unchanged
visit
case
slight
309
mass
about
defined
prove
1987
jp
together
log
lar
1450
milton
lipoprotein
normal
photo
lesser
monitoring
improved
investigators
hypothesis
variability
includes
understood
competing
active
glucose
impact
achieved
run
glycated
guideline
ik
629
insulin
prevalence
holman
med
sas
measurements
detection
added
stwo
face
home
fasting
large
2219
relatively
treatment
long
commons
forschungsbereich
force
reductions
suppl
become
initial
glaxosmithkline
diet
central
history
seems
tion
keynes
easd
feature
baseline
wh
might
record
injection
proactive
mechanism
treat
whose
loennqvist
355
discussion
heart
alt
olympus
started
2005
aims
nr
second
bound
ventura
reported
fall
randomised
593
conducted
professor
salpetriere
service
mk
1726
whether
1464
three
april
was
prediction
two
each
assess
rimm
tropical
waning
participants
unstructured
weight
countries
cardiologie
suggests
02160
progressively
fees
half
limit
available
approved
however
patients
rifai
muscle
one
crp
estimated
631
site
year
usa
paris
laboratory
standardized
among
postprandial
matthews
cowin
proportion
january
dual
reasons
light
abbreviations
634
still
objective
will
stoffwechsel
889
average
nephelometry
pocock
diabetic
variant
squatrito
odds
016
status
produced
047
numbers
carey
wolfenbuttel
dosing
demand
journal
ratio
stopped
then
markers
glyburide
heise
algorithm
blackwell
pd
dja
direct
subcutaneous
decreases
oedema
blood
involving
weeks
keywords
ci
regression
collected
increased
six
wako
biswas
reflect
thus
rifal
daily
similar
1995
evaluated
changes
41st
described
relationships
same
slower
timing
feher
2443
inflammatory
termina
here
lancet
aspects
weaknesses
gliclazide
given
superiority
aged
303
middlesex
article
thiazolidinedione
komajda
between
serum
parallel
endokrinologie
clin
controls
hba1c
though
incident
347
endocrinol
dose
trial
cardiol
894
presumably
pioglitazone
controlled
viberti
0742
entry
524
taking
produces
598
day
determination
240
agents
glycerol
body
characteristics
geneva
using
completers
since
compilation
1996
ethics
diabetes
239
peptide
dargie
metab
intact
upper
assumptions
compare
nc
lost
hanefeld
boards
triplitt
initiation
written
manuscript
prohibited
within
obtained
mh
points
reactivity
dresden
abdominal
elmer
apparently
2004
stratton
peterson
response
because
engl
spain
level
coupled
impossibility
endocrinologists
treacher
smaller
uk
npj
buring
triple
abnormalities
management
federation
decrease
guidelines
925
awaited
2784
ancova
longer
simonson
optimal
used
true
when
background
hosker
gj
incidence
stratum
remote
hanefeldq
scms
627
ii
southall
exclusion
moving
thrombin
4458
shospital
initiating
reagents
enhances
further
base
change
summary
institute
ca
dg
initially
beneficial
step
regulation
sa
1279
implying
comprehensive
untransformed
unknown
adjusted
point
hand
performance
williams
flow
compliance
000
specified
small
therapeutic
association
targets
locked
853
sulphonylureas
1111
repeated
cline
achieving
thrombotic
gh
nearly
iqr
low
rn
diabeticmedicine
across
virtanen
while
tintelize
take
ogld
sjp
glycemic
school
naylor
tions
fell
respects
eckland
persisting
decreased
present
minimal
sj
see
analysed
version
newson
3071
either
common
health
gaskill
prospectively
throughout
review
comparing
ab
maximum
mechanisms
159
task
regimens
hypoglycaemia
012
germany
1008
turnover
size
estimates
metformin
hundal
6s44
responder
terminated
gomiss
completely
haellsten
doses
acid
safety
requires
mb
seely
paid
inadequately
erdmann
oksanen
schedules
protocol
requirement
pharmacology
head
nielsen
172
starting
noted
ew
islet
interestingly
cannot
not
years
loss
conservatively
enzymatic
277
improvements
viljanen
remain
mp
informed
uptake
reduced
standard
deed
bhr
before
contrasted
subgroups
statistically
high
demonstrated
first
athens
overall
1985
sub
2003